Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Organ Preservation in Rectal Cancer (CAO/ARO/AIO-16)
NCT03561142Phase 2Unknown
- Sponsor
- University Hospital Tübingen
- Start
- Jun 2018
- Primary completion
- Apr 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil and oxaliplatin in rectal cancer, sponsored by University Hospital Tübingen. Primary endpoint: Clinical Complete Response Rate at Day 106. Status: unknown.
02
Drugs
fluorouraciloxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03561142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03561142.